Portable medical Dx co attracts $10.8m series B
This article was originally published in Clinica
Executive Summary
Cambridge, Massachusetts start-up T2 Biosystems has raised $10.8m in series B financing which it will use to accelerate the development of what it claims to be the "first portable medical diagnostic products that combine nanotechnology and miniaturised magnetic resonance technology". The funds came from new investors Partners Healthcare and In-Q-Tel and from existing shareholders Flagship Ventures, Polaris Venture Partners and Flybridge Capital Partners. T2's devices will allow accurate, immediate patient testing for "almost any health condition, in nearly any setting", said the company. The technology has demonstrated that it can accurately analyse viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets.